Physician profile
Reezwana Chowdhury
NPI 1316185341
$40,287.98
in general payments reported to CMS, 2019-2025
36 companies · $28K in 2025
The $28K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $362 · 2021: $579 · 2022: $1,997 · 2023: $3,104 · 2024: $5,299 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $19K · Food and Beverage: $8,247 · Consulting Fee: $7,743 · Travel and Lodging: $1,463 · Education: $99.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $18,763.82 |
| Food and Beverage | $8,246.73 |
| Consulting Fee | $7,742.50 |
| Travel and Lodging | $1,462.70 |
| Education | $99.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $29,475.17 | 2024-2025 | Zymfentra, Vegzelma |
| Abbvie INC. | $2,242.90 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Janssen Biotech, INC. | $1,692.97 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,575.41 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $1,107.30 | 2021-2024 | Zeposia |
| Pfizer INC. | $606.59 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $433.15 | 2019-2025 | Xifaxan, Trulance |
| Laborie Medical Technologies Corp. | $395.52 | 2022-2024 | Solar Uroflow System |
| Boston Scientific Corporation | $267.61 | 2022-2023 | |
| Qol Medical, LLC | $228.66 | 2024-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $224.70 | 2019-2024 | Sutab, Suflave |
| E.R. Squibb & Sons, L.L.C. | $217.44 | 2023-2024 | Zeposia |
| Madrigal Pharmaceuticals | $153.60 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $146.02 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $139.99 | 2022-2024 | Ibsrela |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $126.84 | 2022-2025 | Rebyota |
| Janssen Scientific Affairs, LLC | $124.87 | 2023 | Tremfya, Stelara |
| Covidien Lp | $119.37 | 2019 | |
| Intercept Pharmaceuticals, INC. | $116.95 | 2020-2025 | Ocaliva |
| Mallinckrodt Hospital Products INC. | $98.96 | 2023-2025 | Terlivaz |
| Endogastric Solutions, INC | $85.84 | 2022 | |
| Merck Sharp & Dohme LLC | $81.27 | 2019-2020 | |
| Genzyme Corporation | $78.38 | 2023-2025 | |
| Medtronic, INC. | $75.31 | 2022 | |
| Amgen INC. | $63.38 | 2023 | Amjevita, Avsola |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.32 | 2023-2024 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $54.76 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $54.40 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $52.12 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $51.24 | 2023-2024 | Monoferric |
| Aimmune Therapeutics, INC. | $38.70 | 2024 | |
| Digestive Care, INC. | $37.90 | 2025 | Pertzye |
| Ipsen Biopharmaceuticals, INC | $24.26 | 2024 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $22.60 | 2023 | Linzess |
| Redhill Biopharma INC. | $12.48 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reezwana Chowdhury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.